|
US6433154B1
(en)
|
1997-06-12 |
2002-08-13 |
Bristol-Myers Squibb Company |
Functional receptor/kinase chimera in yeast cells
|
|
US6350786B1
(en)
|
1998-09-22 |
2002-02-26 |
Hoffmann-La Roche Inc. |
Stable complexes of poorly soluble compounds in ionic polymers
|
|
ATE400252T1
(de)
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
EP1169038B9
(en)
|
1999-04-15 |
2013-07-10 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
|
AU2001261625B2
(en)
|
2000-05-16 |
2006-04-06 |
Regents Of The University Of Minnesota |
High mass throughput particle generation using multiple nozzle spraying
|
|
BR0210520A
(pt)
|
2001-06-22 |
2004-06-22 |
Pfizer Prod Inc |
Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
|
|
WO2003063831A2
(en)
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Immediate release dosage forms containing solid drug dispersions
|
|
TWI338004B
(en)
|
2004-02-06 |
2011-03-01 |
Bristol Myers Squibb Co |
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
|
|
US7491725B2
(en)
|
2004-02-06 |
2009-02-17 |
Bristol-Myers Squibb Company |
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
|
|
CA2568007A1
(en)
|
2004-05-28 |
2005-12-08 |
Pfizer Products Inc. |
Pharmaceutical compositions with enhanced performance
|
|
WO2007035874A1
(en)
|
2005-09-21 |
2007-03-29 |
Bristol-Myers Squibb Company |
Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof
|
|
US9108217B2
(en)
|
2006-01-31 |
2015-08-18 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
|
WO2007089883A2
(en)
|
2006-01-31 |
2007-08-09 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
|
US7951428B2
(en)
|
2006-01-31 |
2011-05-31 |
Regents Of The University Of Minnesota |
Electrospray coating of objects
|
|
EP1920767A1
(en)
|
2006-11-09 |
2008-05-14 |
Abbott GmbH & Co. KG |
Melt-processed imatinib dosage form
|
|
EP2089003A1
(en)
|
2006-11-09 |
2009-08-19 |
Abbott GmbH & Co. KG |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
US9040816B2
(en)
|
2006-12-08 |
2015-05-26 |
Nanocopoeia, Inc. |
Methods and apparatus for forming photovoltaic cells using electrospray
|
|
EP2162120B1
(en)
|
2007-06-04 |
2016-05-04 |
Bend Research, Inc |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
|
US20100266692A1
(en)
|
2007-07-13 |
2010-10-21 |
Corey Jay Bloom |
Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
|
|
PL2508523T5
(pl)
|
2007-10-23 |
2020-08-10 |
Teva Pharmaceutical Industries Ltd. |
Odmiany polimorficzne dasatynibu i sposób ich wytwarzania
|
|
WO2009061787A1
(en)
|
2007-11-05 |
2009-05-14 |
Nanocopoeia, Inc. |
Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity
|
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
CZ20098A3
(cs)
|
2009-01-13 |
2010-07-21 |
Zentiva, K.S. |
Lékové formy inhibitoru tyrosinových kináz
|
|
WO2011146611A1
(en)
*
|
2010-05-18 |
2011-11-24 |
Abon Pharmaceuticals, Llc |
Modified gastroretentive drug delivery system for amine drugs
|
|
BR112012031516A2
(pt)
|
2010-06-09 |
2016-11-08 |
Abbott Lab |
dispersões sólidas contendo inibidores de quinase
|
|
AU2011303849A1
(en)
|
2010-09-14 |
2013-04-04 |
Nanologica Ab |
Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
|
|
EP2665559B1
(en)
|
2011-01-19 |
2018-07-18 |
Washington University |
Electrohydrodynamic atomization nozzle emitting a liquid sheet
|
|
CA2849331A1
(en)
|
2011-10-13 |
2013-04-18 |
Genentech, Inc. |
Treatment of pharmacological-induced hypochlorhydria
|
|
MX371297B
(es)
|
2012-01-13 |
2020-01-24 |
Xspray Microparticles Ab |
Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.
|
|
EP2802314B1
(en)
|
2012-01-13 |
2020-11-25 |
XSpray Microparticles AB |
A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
|
|
US9249134B2
(en)
|
2013-03-26 |
2016-02-02 |
Cadila Healthcare Limited |
Process for preparation of amorphous form of dasatinib
|
|
AU2014295143B9
(en)
|
2013-07-25 |
2017-03-23 |
Basf Se |
Salts of Dasatinib in amorphous form
|
|
HU231013B1
(hu)
|
2014-05-26 |
2019-11-28 |
Egis Gyógyszergyár Zrt. |
Dasatinib sók
|
|
US20150110871A1
(en)
|
2014-06-02 |
2015-04-23 |
David Wong |
Gastric retentive tablet compositions
|
|
PT107846B
(pt)
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
EP3223798A1
(en)
|
2014-11-25 |
2017-10-04 |
Nanocopoeia LLC |
Amorphous nanoparticles prepared by electrospraying
|
|
US20160175881A1
(en)
|
2014-12-22 |
2016-06-23 |
Nanocopoeia, Llc |
Electrospray methods, electrospray systems, and methods of forming crystalline particles
|
|
PT108368B
(pt)
|
2015-03-31 |
2018-11-05 |
Hovione Farm S A |
Produção contínua de partículas
|
|
WO2017108605A1
(en)
*
|
2015-12-22 |
2017-06-29 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous dasatinib
|
|
WO2017134615A1
(en)
|
2016-02-03 |
2017-08-10 |
Dr. Reddy's Laboratories Limited |
Solid state forms of dasatinib and processes for their preparation
|
|
WO2018078392A1
(en)
|
2016-10-29 |
2018-05-03 |
Cipla Limited |
Polymorphs of dasatinib
|
|
JP7777915B2
(ja)
*
|
2017-03-27 |
2025-12-01 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
がんを処置する組成物及び方法
|
|
CA3068609A1
(en)
*
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of cystic fibrosis
|
|
TWI831259B
(zh)
|
2018-06-15 |
2024-02-01 |
漢達生技醫藥股份有限公司 |
包含達沙替尼十二烷基硫酸鹽組合物的膠囊
|
|
CN113573712A
(zh)
|
2019-02-18 |
2021-10-29 |
斯莱班克制药有限责任公司 |
尼洛替尼的药物组合物
|
|
US10799459B1
(en)
|
2019-05-17 |
2020-10-13 |
Xspray Microparticles Ab |
Rapidly disintegrating solid oral dosage forms containing dasatinib
|
|
IL294928A
(en)
|
2020-01-24 |
2022-09-01 |
Nanocopoeia Llc |
Amorphous solid dispersions of dasatinib and uses thereof
|
|
WO2022040446A1
(en)
|
2020-08-19 |
2022-02-24 |
Nanocopoeia, Llc |
Amorphous pazopanib particles and pharmaceutical compositions thereof
|
|
CA3202761A1
(en)
|
2020-11-25 |
2022-06-02 |
Nanocopoeia, Llc |
Amorphous cabozantinib particles and uses thereof
|
|
US11529351B2
(en)
|
2021-01-21 |
2022-12-20 |
Xspray Pharma Ab |
Fast dissolving pharmaceutical compositions
|
|
US11980619B2
(en)
*
|
2021-07-28 |
2024-05-14 |
Nanocopoeia, Llc |
Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
|